Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2010 May;95(5):852-3.
doi: 10.3324/haematol.2009.019224. Epub 2010 Feb 9.

Impact of the type of the BCR-ABL fusion transcript on the molecular response in pediatric patients with chronic myeloid leukemia

Meinolf Suttorp, Christian Thiede, Josephine T Tauer, Ursula Range, Brigitte Schlegelberger, Nils von Neuhoff
Comparative Study

Impact of the type of the BCR-ABL fusion transcript on the molecular response in pediatric patients with chronic myeloid leukemia

Meinolf Suttorp et al. Haematologica. 2010 May.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Time course of the transcript ratio BCR-ABL/ABL in individual patients exhibiting either the e13a2 rearrangement type (red dots) or the e14a2 type (green dots) in pediatric patients with chronic myeloid leukemia under ongoing imatinib treatment. Full lines denote the best fitted curves adapted by logarithmic function for decline over time while dotted lines show the upper and lower limits of confidence (red lines: e13a2; green lines e14a2).
See this image and copyright information in PMC

Comment on

References

    1. Lucas CM, Harris RJ, Giannoudis A, Davies A, Knight K, Watmough SJ, et al. Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript. Haematologica. 2009;94(10):1362–7. - PMC - PubMed
    1. Champagne MA, Capdeville R, Krailo M, Qu W, Peng B, Rosamilia M, et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. Blood. 2004;104(9):2655–60. - PubMed
    1. Millot F, Guilhot J, Nelken B, Leblanc T, De Bont ES, Bekassy AN, et al. Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation. Leukemia. 2006;20(2):187–92. - PubMed
    1. Suttorp M. Innovative approaches of targeted therapy for chronic myeloid leukaemia of childhood in combination with paediatric haematopoietic stem cell transplantation (Review) Bone Marrow Transplant. 2008;42(Suppl 2):S40–S46. - PubMed
    1. Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors - review and recommendations for “harmonizing” current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108(1):28–37. - PMC - PubMed